Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6424
    -0.0002 (-0.03%)
     

  • OIL

    83.49
    +0.76 (+0.92%)
     

  • GOLD

    2,416.30
    +18.30 (+0.76%)
     

  • Bitcoin AUD

    99,860.23
    +861.48 (+0.87%)
     

  • CMC Crypto 200

    1,376.74
    +64.12 (+4.88%)
     

  • AUD/EUR

    0.6026
    -0.0004 (-0.07%)
     

  • AUD/NZD

    1.0899
    +0.0024 (+0.22%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,149.56
    -244.75 (-1.41%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,998.85
    +223.47 (+0.59%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Instadose Pharma Corp. (INSD) Investors

Kirby McInerney LLP
·2-min read

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Instadose Pharma Corp. (“Instadose” or the “Company”) (OTC: INSD). The investigation concerns whether Instadose has violated the federal securities laws and/or engaged in other unlawful business practices.

On November 23, 2021, the U.S. Securities and Exchange Commission (“SEC”) announced a temporary suspension in the trading of Instadose securities due to concerns regarding the adequacy and accuracy of information about the Company in the marketplace. The SEC specifically noted stock price and volume increases of Instadose stock unsupported by the Company’s assets and financial information, trading that may be associated with individuals related to a control person at the Company, and operations at the Company’s Canadian affiliate. On this news, the Company’s share price declined by $3.69 per share, or approximately 13%, from $28.30 per share to close at $24.61 per share on November 23, 2021.

If you purchased or otherwise acquired Instadose securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

ADVERTISEMENT

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com